Luigi Elio Adinolfi

List of Publications by Year
in descending order

96 papers	5,649 citations	94269 37 h-index	79541 73 g-index
97 all docs	97 docs citations	97 times ranked	6009 citing authors

#	Article	IF	Citations
1	Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology, 2001, 33, 1358-1364.	3.6	922
2	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, 2006, 130, 1636-1642.	0.6	517
3	Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology, 2004, 126, 586-597.	0.6	433
4	Hepatitis B virus burden in developing countries. World Journal of Gastroenterology, 2015, 21, 11941.	1.4	220
5	Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World Journal of Hepatology, 2013, 5, 528.	0.8	178
6	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis, 2012, 221, 496-502.	0.4	164
7	Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. British Journal of Haematology, 2001, 113, 590-595.	1.2	161
8	Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. World Journal of Gastroenterology, 2014, 20, 3410.	1.4	140
9	Nonalcoholic fatty liver disease: Evolving paradigms. World Journal of Gastroenterology, 2017, 23, 6571-6592.	1.4	138
10	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. World Journal of Gastroenterology, 2015, 21, 2269.	1.4	134
11	Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology, 2005, 41, 995-1003.	3.6	113
12	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. Journal of Diabetes Research, 2020, 2020, 1-8.	1.0	106
13	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	1.8	98
14	Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. Journal of Hepatology, 2008, 48, 399-406.	1.8	97
15	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovascular Diabetology, 2021, 20, 145.	2.7	91
16	Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Digestive Diseases and Sciences, 2001, 46, 1677-1683.	1.1	88
17	NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences, 2016, 17, 803.	1.8	85
18	Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis, 2013, 231, 22-26.	0.4	80

#	Article	IF	Citations
19	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovascular Diabetology, 2019, 18, 24.	2.7	78
20	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.4	78
21	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-8.	1.0	69
22	Hepatitis C and diabetes: the inevitable coincidence?. Expert Review of Anti-Infective Therapy, 2009, 7, 293-308.	2.0	66
23	Hepatitis C virus clearance by directâ€acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1379-1382.	1.4	64
24	Metformin: An old drug against old age and associated morbidities. Diabetes Research and Clinical Practice, 2020, 160, 108025.	1.1	64
25	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. Processes, 2021, 9, 135.	1.3	62
26	Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opinion on Pharmacotherapy, 2011, 12, 2215-2234.	0.9	61
27	Liver fibrosis by FibroScan^{Â®} independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	1.9	59
28	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by directâ€acting antiviral therapy: A prospective study. Diabetes, Obesity and Metabolism, 2020, 22, 2408-2416.	2.2	58
29	Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study. Diabetes/Metabolism Research and Reviews, 2018, 35, e3113.	1.7	55
30	<scp>TM</scp>6<scp>SF</scp>2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of <scp>PNPLA</scp>3 polymorphism. Liver International, 2015, 35, 1959-1963.	1.9	51
31	Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers, 2020, 12, 1351.	1.7	50
32	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. Journal of Translational Medicine, 2019, 17, 292.	1.8	49
33	Chronic Hepatitis C Virus Infection and Depression. Clinics in Liver Disease, 2017, 21, 517-534.	1.0	46
34	Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 334-340.	2.4	44
35	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses, 2021, 13, 2249.	1.5	42
36	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2345-2353.	1.1	40

#	Article	IF	Citations
37	Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. Clinical Infectious Diseases, 2022, 75, e403-e409.	2.9	40
38	Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology, 1999, 30, 1530-1531.	3.6	39
39	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World Journal of Gastroenterology, 2017, 23, 1458.	1.4	38
40	Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, 2020, 1, .	1.5	37
41	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS ONE, 2020, 15, e0243700.	1.1	36
42	High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. Diabetes Research and Clinical Practice, 2019, 150, 236-244.	1.1	35
43	Seasonal variations of hyponatremia in the emergency department: Age-related changes. American Journal of Emergency Medicine, 2017, 35, 749-752.	0.7	33
44	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. Digestive Diseases and Sciences, 2019, 64, 3013-3019.	1.1	33
45	Diseases associated with electrolyte imbalance in the ED: age-related differences. American Journal of Emergency Medicine, 2016, 34, 1923-1926.	0.7	32
46	Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. World Journal of Gastroenterology, 2018, 24, 4617-4621.	1.4	31
47	Metformin lactic acidosis: Should we still be afraid?. Diabetes Research and Clinical Practice, 2019, 157, 107879.	1.1	30
48	The predictive value of steatosis in hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2013, 7, 205-213.	1.4	26
49	Circulating MiRNA-195-5p and -451a in Diabetic Patients with Transient and Acute Ischemic Stroke in the Emergency Department. International Journal of Molecular Sciences, 2020, 21, 7615.	1.8	22
50	Sonoporation by microbubbles as gene therapy approach against liver cancer. Oncotarget, 2018, 9, 32182-32190.	0.8	22
51	Circulating MiRNA-195-5p and -451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department. Journal of Clinical Medicine, 2019, 8, 130.	1.0	19
52	Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. Clinical Transplantation, 2001, 15, 415-420.	0.8	18
53	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1123-1130.	1.4	18
54	Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by directâ€acting antivirals. JGH Open, 2020, 4, 713-721.	0.7	18

#	Article	IF	Citations
55	Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. Infection, 2018, 46, 793-799.	2.3	15
56	Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a realâ€life setting: A multicentre prospective study. Respirology, 2020, 25, 535-542.	1.3	15
57	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi Journal of Gastroenterology, 2018, 24, 25.	0.5	15
58	Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Reviews in Cardiovascular Medicine, 2022, 23, 0106.	0.5	15
59	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World Journal of Hepatology, 2014, 6, 677.	0.8	14
60	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection, 2018, 46, 231-238.	2.3	13
61	The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. Expert Review of Anti-Infective Therapy, 2018, 16, 595-597.	2.0	13
62	Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Medica, 2021, 112, 188-200.	0.3	13
63	Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C. PLoS ONE, 2014, 9, e99450.	1.1	13
64	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World Journal of Hepatology, 2015, 7, 2363.	0.8	13
65	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clinical Gastroenterology and Hepatology, 2020, 18, 517-519.	2.4	12
66	Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus. Antiviral Therapy, 2018, 23, 11-21.	0.6	11
67	Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Review of Clinical Immunology, 2018, 14, 1089-1099.	1.3	11
68	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. Scandinavian Journal of Gastroenterology, 2019, 54, 1274-1282.	0.6	11
69	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107684.	1.2	11
70	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. Digestive Diseases and Sciences, 2015, 60, 3005-3010.	1.1	10
71	Factors affecting longâ€term changes of liver stiffness in directâ€acting antiâ€hepatitis C virus therapy: A multicentre prospective study. Journal of Viral Hepatitis, 2022, 29, 26-34.	1.0	10
72	Hepatitis B and C virus infection and risk of haematological malignancies. Journal of Viral Hepatitis, 2020, 27, 4-12.	1.0	9

#	Article	IF	Citations
73	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. Digestive and Liver Disease, 2016, 48, 1364-1369.	0.4	8
74	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2021, 15, 643-656.	1.4	8
75	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. PLoS ONE, 2021, 16, e0256903.	1.1	8
76	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Scientific Reports, 2022, 12, 5771.	1.6	7
77	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemicâ€"Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	1.3	7
78	Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Frontiers in Immunology, 2022, 13, 882064.	2.2	7
79	The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clinical Oral Investigations, 2022, 26, 5409-5417.	1.4	6
80	Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. Hepatobiliary Surgery and Nutrition, 2018, 7, 143-146.	0.7	5
81	Early Lymphopenia and Infections in Nontraumatic Subarachnoid Hemorrhage Patients. Journal of Neurosurgical Anesthesiology, 2022, 34, 243-247.	0.6	5
82	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.	0.8	5
83	Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. Infezioni in Medicina, 2014, 22, 331-6.	0.7	5
84	Acute rhabdomiolisys in healthy woman. American Journal of Emergency Medicine, 2016, 34, 113.e1-113.e2.	0.7	4
85	Atypical Presentation of a Rare Parasitic Infection with Fasciola hepatica: A Multidisciplinary Case Report. American Journal of Case Reports, 2020, 21, e924704.	0.3	4
86	PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. International Journal of Cardiology, 2014, 172, 291-292.	0.8	3
87	Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. Infezioni in Medicina, 2015, 23, 134-9.	0.7	3
88	Circulating miRNA-195-5p and -451a in Patients with Acute Hemorrhagic Stroke in Emergency Department. Life, 2022, 12, 763.	1.1	3
89	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1806-1812.	1.1	2
90	Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. Journal of Scleroderma and Related Disorders, 2021, 6, 256-263.	1.0	2

#	Article	IF	Citations
91	No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. Infezioni in Medicina, 2018, 26, 244-248.	0.7	2
92	Clinical impact of direct-acting antiviral treatment on patients with hepatitis C virusâ€“related oral lichen planus. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 131, e113.	0.2	1
93	Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study. Infezioni in Medicina, 2016, 24, 278-286.	0.7	1
94	AB0648â€…CORRELATIONS BETWEEN NEUTROPHIL/LYMPHOCYTE RATIO AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
95	Viral Hepatitis C. , 2020, , 181-195.		0
96	Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant. Infezioni in Medicina, 2015, 23, 285-7.	0.7	0